What's Happening?
Representative Suzanne Bonamici (D-OR) is co-leading the House legislation for the bipartisan Alan Reinstein Ban Asbestos Now (ARBAN) Act of 2026 (H.R. 5373). This legislative effort aims to establish a national framework to prohibit commercial asbestos,
close existing regulatory gaps, and provide greater regulatory certainty regarding asbestos use and exposure. The Asbestos Disease Awareness Organization (ADAO) reports strong support for the bill, highlighting sustained engagement with lawmakers and the prevention community. The organization also hosted its 20th Congressional Staff Briefing, where experts presented evidence on ongoing asbestos risks and the necessity of the ARBAN Act. This initiative comes as the ADAO continues to advance federal legal cases related to asbestos, including awaiting a decision from the U.S. Court of Appeals for the Fifth Circuit concerning the EPA’s March 2024 chrysotile asbestos rule and addressing delays in the EPA’s legacy asbestos rule.
Why It's Important?
The ARBAN Act is crucial for public health in the U.S. as asbestos exposure is linked to various cancers, including lung cancer and mesothelioma, with no safe level of exposure. The legislation seeks to prevent future exposure and save lives by banning all imports and use of all types of asbestos fibers. The ongoing presence of legacy asbestos in millions of schools, homes, and workplaces across the U.S. puts the average American at risk, contributing to an estimated 40,000 deaths annually from asbestos-related illnesses. A comprehensive ban would address these pervasive risks, particularly as current regulations are deemed insufficient by advocates. The bill's bipartisan nature suggests a broad recognition of the public health threat, aiming to create a durable national framework that protects workers, families, and communities from this hazardous material.
What's Next?
The ARBAN Act will continue to seek passage in Congress, with ongoing advocacy from organizations like the ADAO to build further bipartisan support. The ADAO plans to maintain its focus on defending science-based regulations, compelling overdue EPA action on asbestos, demanding government transparency, and expanding access to prevention resources. Concurrently, legal battles related to asbestos regulations will proceed, including the awaited decision from the Fifth Circuit on the EPA’s chrysotile asbestos rule and the EPA’s targeted June 2027 deadline for its proposed legacy asbestos rule. These legislative and legal efforts aim to strengthen protections against asbestos exposure and ensure a comprehensive ban is enacted, ultimately working towards eliminating asbestos-related health risks in the United States.
Beyond the Headlines
The push for the ARBAN Act highlights a broader societal challenge in addressing long-standing environmental health hazards. The continued presence of asbestos in older infrastructure, including schools, underscores systemic issues in public health protection and regulatory enforcement. The debate also touches upon the balance between industrial interests, which sometimes argue against stringent regulations due to economic impact, and public health imperatives. The ADAO's multi-pronged approach, integrating scientific research, public education, policy advocacy, and strategic litigation, exemplifies how civil society organizations can drive significant policy change. This ongoing struggle reflects a commitment to translating scientific findings into stronger protections, emphasizing that prevention and accountability are critical for safeguarding public health against known carcinogens.
